Rob Ortmann

Rob Ortmann is the Vice President of Clinical Development at Nkarta, Inc., where they apply their extensive expertise in immunology drug development. With a decade of experience in the pharmaceutical industry, Rob specializes in early and late-phase clinical trials, translational medicine, and the implementation of novel trial designs. Previously, they held leadership roles as Division Director in Rheumatology at two academic medical centers and served in various clinical development positions at notable companies, including AstraZeneca and Eli Lilly and Company. Rob graduated with a Doctor of Medicine from Case Western Reserve University School of Medicine and completed post-doctoral training at the National Institutes of Health.